PMID- 34818666
OWN - NLM
STAT- MEDLINE
DCOM- 20220221
LR  - 20221214
IS  - 1738-8872 (Electronic)
IS  - 1017-7825 (Print)
IS  - 1017-7825 (Linking)
VI  - 32
IP  - 1
DP  - 2022 Jan 28
TI  - Effects of 3'-isovaleryl-4'-senecioylkhellactone from Peucedanum japonicum 
      Thunberg on PMA-Stimulated Inflammatory Response in A549 Human Lung Epithelial 
      Cells.
PG  - 81-90
LID - 10.4014/jmb.2107.07001 [doi]
AB  - Peucedanum japonicum Thunberg (PJT) has been used in traditional medicine to 
      treat colds, coughs, fevers, and other inflammatory diseases. The goal of this 
      study was to investigate whether 3'-isovaleryl-4'-senecioylkhellactone (IVSK) 
      from PJT has anti-inflammatory effects on lung epithelial cells. The 
      anti-inflammatory effects of IVSK were evaluated using phorbol 12-myristate 
      13-acetate (PMA)-stimulated A549 cells and regular human lung epithelial cells as 
      a reference. IVSK reduced the secretion of the inflammatory mediators interleukin 
      (IL)-8 and monocyte chemoattractant protein-1 (MCP-1), and the mRNA expression of 
      IL-6, IL-8, MCP-1, and IL-1beta. Additionally, it inhibited the phosphorylation of 
      IkappaB kinase (IKK), p65, Ikappa-Balpha, and mitogen-activated protein kinases (MAPKs) p38, 
      JNK, and ERK in A549 cells stimulated with PMA. Moreover, the binding affinity of 
      activator protein-1 (AP-1) and nuclear factor-kappaB (NF-kappaB) was significantly 
      reduced in the luciferase assay, while nuclear translocation was markedly 
      inhibited by IVSK in the immunocytochemistry. These findings indicate that IVSK 
      can protect against inflammation through the AP-1 and NF-kappaB pathway and could 
      possibly be used as a lead compound for the treatment of inflammatory lung 
      diseases.
FAU - Hwang, Daseul
AU  - Hwang D
AD  - Natural Medicine Research Center, Korea Research Institute of Bioscience and 
      Biotechnology, Cheongju 28116, Republic of Korea.
AD  - College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of 
      Korea.
FAU - Ryu, Hyung Won
AU  - Ryu HW
AD  - Natural Medicine Research Center, Korea Research Institute of Bioscience and 
      Biotechnology, Cheongju 28116, Republic of Korea.
FAU - Park, Ji-Won
AU  - Park JW
AD  - Natural Medicine Research Center, Korea Research Institute of Bioscience and 
      Biotechnology, Cheongju 28116, Republic of Korea.
FAU - Kim, Jung-Hee
AU  - Kim JH
AD  - Natural Medicine Research Center, Korea Research Institute of Bioscience and 
      Biotechnology, Cheongju 28116, Republic of Korea.
FAU - Kim, Doo-Young
AU  - Kim DY
AD  - Natural Medicine Research Center, Korea Research Institute of Bioscience and 
      Biotechnology, Cheongju 28116, Republic of Korea.
FAU - Oh, Jae-Hoon
AU  - Oh JH
AD  - Natural Medicine Research Center, Korea Research Institute of Bioscience and 
      Biotechnology, Cheongju 28116, Republic of Korea.
AD  - College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of 
      Korea.
FAU - Kwon, Ok-Kyoung
AU  - Kwon OK
AD  - Natural Medicine Research Center, Korea Research Institute of Bioscience and 
      Biotechnology, Cheongju 28116, Republic of Korea.
FAU - Han, Sang-Bae
AU  - Han SB
AD  - College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of 
      Korea.
FAU - Ahn, Kyung-Seop
AU  - Ahn KS
AD  - Natural Medicine Research Center, Korea Research Institute of Bioscience and 
      Biotechnology, Cheongju 28116, Republic of Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - J Microbiol Biotechnol
JT  - Journal of microbiology and biotechnology
JID - 9431852
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (CXCL8 protein, human)
RN  - 0 (Cytokines)
RN  - 0 (IL1B protein, human)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-8)
RN  - 0 (Phorbol Esters)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factor AP-1)
RN  - 20839-06-9 (phorbol-12-myristate)
RN  - EC 2.7.11.10 (I-kappa B Kinase)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
SB  - IM
MH  - A549 Cells/drug effects
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Apiaceae/*metabolism
MH  - Cytokines/metabolism
MH  - Epithelial Cells/*drug effects
MH  - Humans
MH  - I-kappa B Kinase/metabolism
MH  - Inflammation
MH  - Inflammation Mediators/metabolism
MH  - Interleukin-1beta
MH  - Interleukin-8
MH  - Lung/*drug effects
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - Phorbol Esters/*pharmacology
MH  - RNA, Messenger/metabolism
MH  - Transcription Factor AP-1/metabolism
MH  - p38 Mitogen-Activated Protein Kinases/metabolism
PMC - PMC9628833
OTO - NOTNLM
OT  - 3'-isovaleryl-4'-senecioylkhellactone
OT  - AP-1
OT  - NF-kappaB
OT  - Peucedanum japonicum Thunberg
OT  - inflammation
COIS- Conflict of Interest The authors have no financial conflicts of interest to 
      declare.
EDAT- 2021/11/25 06:00
MHDA- 2022/02/22 06:00
PMCR- 2021/11/14
CRDT- 2021/11/24 20:10
PHST- 2021/07/02 00:00 [received]
PHST- 2021/11/10 00:00 [revised]
PHST- 2021/11/12 00:00 [accepted]
PHST- 2021/11/25 06:00 [pubmed]
PHST- 2022/02/22 06:00 [medline]
PHST- 2021/11/24 20:10 [entrez]
PHST- 2021/11/14 00:00 [pmc-release]
AID - jmb.2107.07001 [pii]
AID - jmb-32-1-81 [pii]
AID - 10.4014/jmb.2107.07001 [doi]
PST - ppublish
SO  - J Microbiol Biotechnol. 2022 Jan 28;32(1):81-90. doi: 10.4014/jmb.2107.07001.